Skip to content

Abstract B122: The timing matters: schedule-dependent optimization of gemcitabine and RAS(ON) inhibition in pancreatic cancer, a call for a new approach to clinical trial design

Sep 2026 · Cancer Research · Vol 86, pp. B122-B122 · 0 citations

TL;DR

It is shown that GEM followed by RAS inhibitor (GEM→RASi) scheduling is associated with improved survival and altered tumor growth dynamics relative to reverse scheduling and monotherapies, and favorable survival trends compared to concurrent treatment, with reduced total agent exposure.

Abstract

Recent data published from the RASolute 302 trial (NCT06625320), showing that RAS inhibition nearly doubles median survival to 13.2 months compared to 6.7 months with standard-of-care chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC), received an ovation when presented at the 2026 ASCO Oncology meeting. Despite these advances, most patients develop resistance, indicating that RAS inhibition alone is unlikely to provide durable control and that rational combination strategies will be required. The current phase 3 RASolute 303 clinical trial combines RAS(ON) inhibition with standard-of-care chemotherapeutic regimens using concurrent administration. This approach, based on coordination, has not been evaluated for efficacy and tolerability against alternative scheduling strategies. In fact, in PDAC models, the scheduling of gemcitabine (GEM) before nab-paclitaxel improves therapeutic efficacy compared to concurrent administration. These findings suggest that the timing of treatment is a biological variable to be exploited to enhance patient outcomes. Herein, we assessed whether the timed-sequencing of GEM and RAS(ON) inhibitor daraxonrasib (RMC-6236; hereafter RASi) administration alters therapeutic outcomes in an immunocompetent orthotopic PDAC model. In this study, using a clinically tractable sequencing paradigm, we compared concurrent therapy with sequential regimens in which GEM preceded RASi (GEM→RASi) or vice versa (RASi→GEM). Specifically, we tested six different arms to this pre-clinical trial to assess relevant translational endpoints including: 1) tumor growth kinetics; 2) survival outcomes; 3) tolerability and systemic effects. We show that GEM followed by RAS inhibitor (GEM→RASi) scheduling is associated with improved survival and altered tumor growth dynamics relative to reverse scheduling and monotherapies, and favorable survival trends compared to concurrent treatment, with reduced total agent exposure. These findings identify timed-treatment scheduling as a modifiable variable with direct implications for the clinical integration of RAS(ON) inhibitors. Mechanistically, a strong putative explanation for the observed sequencing effect may lie in gemcitabine-induced cell cycle redistribution. Ongoing studies are evaluating whether GEM arrests surviving cells at the G1/S transition, a phase associated with heightened RAS pathway dependency, during which oncogenic KRAS activity is essential for cell cycle re-entry. RAS inhibitors are currently under clinical evaluation in combination with standard-of-care chemotherapy in PDAC. Our data question the assumption that concurrent administration is optimal, instead suggesting that defined therapeutic sequencing may enhance efficacy, while reducing overall chemotherapy exposure and eventual therapeutic resistance. This is an important consideration given that adverse events to extended regimens are frequently dose-limiting, and the logistical burden of infusion-based therapy represents a meaningful and sometimes prohibitive barrier for patients. Jonathan Brody. The timing matters: schedule-dependent optimization of gemcitabine and RAS(ON) inhibition in pancreatic cancer, a call for a new approach to clinical trial design [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B122.

View source

Similar papers

Sep 2026

Abstract IA012: A New Perspective: Clinical Trials in the Era of RAS Inhibitors

The demonstration of an overall survival benefit for RAS(ON) multi-selective inhibition in previously treated metastatic pancreatic ductal adenocarcinoma (RASolute 302) establishes the first randomised evidence for RAS-directed therapy in this disease. Previously, biomarker-directed treatment in PDAC reached a minori...

C. B. Westphalen · 0 citations
Open access Sep 2026

Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma.

Advanced pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with limited benefits from conventional chemotherapy. Daraxonrasib is an oral, noncovalent RAS(ON) multi-selective inhibitor that forms a ternary complex with cyclophilin A and GTP-bound RAS, blocking downstream signaling across multiple mutant and...

Yue-Yi Sun, Chen Pang, Jian-Jun Gao · 0 citations
Sep 2026

Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX

The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.

B. Huffman, Haeseong Park, N. Jackson et al. · 0 citations
#data science Review Open access Oct 2026

Biweekly gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a systematic review

Pancreatic cancer is associated with high morbidity and mortality. Gemcitabine plus nab-paclitaxel (GA), along with FOLFIRINOX and NALIRIFOX, is a standard first-line treatment for advanced/metastatic pancreatic ductal adenocarcinoma (mPDAC). However, the standard GA schedule (days 1, 8, and 15 of a 28-day cycle)...

C. Hoyek, C. Eslinger, Angelo Pirozzi et al. · 0 citations
Open access Nov 2026

A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors.

PURPOSE Preclinical data suggest that the anti-cancer efficacy of ATR inhibitors can be synergistically enhanced by low-dose gemcitabine. To test the clinical feasibility of this regimen, we conducted a phase 1 trial of low-dose gemcitabine combined with the ATR inhibitor elimusertib (BAY1895344). PATIENTS AND METHOD...

T. Jayakrishnan, Rebecca L. Porter, Alice P. Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.